{"id":499994,"date":"2021-06-02T08:28:26","date_gmt":"2021-06-02T12:28:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/"},"modified":"2021-06-02T08:28:26","modified_gmt":"2021-06-02T12:28:26","slug":"akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/","title":{"rendered":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications"},"content":{"rendered":"

\nCompany launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials
\n<\/h2>\n
\n

MARLBOROUGH, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company\u00ae<\/sup>, today announced the launch of Advanced Biopharma Solutions (ABS) as a premium service for biopharmaceutical companies interested in adopting multiplex immunofluorescence (mIF) workflows and spatial biomarker development in their translational pathology and immunotherapy programs.<\/p>\n

ABS is a component of Akoya\u2019s broader Clinical Research Program, a strategic initiative which aims to support the implementation of the Company\u2019s Phenoptics\u2122 mIF platform and spatial phenotypic signatures for precision pathology, through partnerships with academic medical centers, contract research organizations (CROs), reference labs, and the biopharmaceutical industry.<\/p>\n

ABS leverages the Company\u2019s knowledge and leadership in spatial phenotyping to accelerate biopharmaceutical companies\u2019 quest for accurate predictive biomarkers, with the aim of improving trial design and drug development success rates. Through ABS, Akoya\u2019s biopharmaceutical partners can access its deep mIF expertise, custom assay development capabilities, capacity to support clinical trial assays, and image analysis and interpretative skills.<\/p>\n

\u201cBy launching ABS, Akoya is offering its spatial biology expertise to the biopharma industry to enable the adoption of spatial-biomarker informed clinical trial strategies and, we believe, solve some of immunotherapy\u2019s toughest challenges,\u201d said Akoya Chief Executive Officer Brian McKelligon. \u201cOur hope is that the partnerships through ABS can catalyze our understanding of tumor immune biology, spatial biomarker discovery and eventually enhance the success of precision medicine.\u201d<\/p>\n

Immunotherapies are effective in certain subsets of cancer patients, but accurate determination of which patients are likely to respond has been challenging with current biomarker technologies, leading to high clinical trial failure rates and inefficiencies in cancer care. A multi-institutional study of immuno-oncology biomarker modalities, published in JAMA Oncology <\/em>in 2019,<\/em> demonstrated that mIF-based spatial biomarkers outperformed other biomarker testing approaches\u2014 such as gene expression profiling, tumor mutational burden (TMB) assessment, and PD-L1 immunohistochemistry (IHC) \u2014 for predicting patient response to immunotherapy treatment.<\/p>\n

Spatial biology is a rapidly emerging scientific discipline that has the potential to elucidate the immune biology of cancer in greater detail by analyzing the spatial architecture of tumor tissue sections and mapping how tumor and immune cells organize and interact within the tumor microenvironment. These insights have implications for streamlining drug development, clinical trials, and biomarker discovery, and are currently being applied to immunotherapy research.<\/p>\n

A cutting-edge tool for spatial biology research is Akoya\u2019s Phenoptics\u2122 mIF platform. The platform has been adopted by the top cancer centers and biopharma companies globally, due to its robust spatial phenotyping capabilities and its ability to support large-scale translational and clinical research studies.<\/p>\n

Representatives from Akoya\u2019s ABS team will be exhibiting at the American Society of Clinical Oncology (ASCO) Virtual Meeting from June 4 to 8 at booth 5067a. More information can also be found at akoyabio.com\/advanced-biopharma-solutions<\/a>.<\/p>\n

\n About Akoya Biosciences <\/strong>\n <\/p>\n

As The Spatial Biology Company\u00ae<\/sup>, Akoya Biosciences\u2019 mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX<\/em>\u00ae<\/sup> and Phenoptics<\/em>\u2122 platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. For more information, please visit https:\/\/www.akoyabio.com\/<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d under applicable securities laws. In some cases, such statements can be identified by words such as: \u201cmay,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding our ability to achieve our business strategies, growth, or other future events or conditions. Such statements are based on our current beliefs, expectations, and assumptions about future events or conditions, which are subject to inherent risks and uncertainties, including\u00a0the risks and uncertainties discussed in the filings we make from time to time with the Securities and Exchange Commission. Actual results may differ materially from those indicated in forward-looking statements, and you should not place undue reliance on them. All statements herein are based only on information currently available to us and speak only as of the date hereof. Except as required by law, we undertake no obligation to update any such statement.<\/p>\n

\n Investor Contact:<\/strong>
\n
David Deuchler
Gilmartin Group LLC
investors@akoyabio.com<\/a><\/p>\n

\n Media contact:<\/strong>
\n
Michelle Linn
Bioscribe Inc
774-696-3803
michelle@bioscribe.com<\/a><\/p>\n

\n JAMA Oncology<\/a>: Paper reference: Steve Lu et al. Comparison of Biomarker Modalities for Predicting Response to PD-1\/PD-L1 Checkpoint Blockade. JAMA Oncology. doi: 10.1001\/jamaoncol.2019.1549<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials MARLBOROUGH, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company\u00ae, today announced the launch of Advanced Biopharma Solutions (ABS) as a premium service for biopharmaceutical companies interested in adopting multiplex immunofluorescence (mIF) workflows and spatial biomarker development in their translational pathology and immunotherapy programs. ABS is a component of Akoya\u2019s broader Clinical Research Program, a strategic initiative which aims to support the implementation of the Company\u2019s Phenoptics\u2122 mIF platform and spatial phenotypic signatures for precision pathology, through partnerships with academic medical centers, contract research organizations (CROs), reference labs, and the biopharmaceutical … <\/p>\n

Continue reading “Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499994","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAkoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials MARLBOROUGH, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company\u00ae, today announced the launch of Advanced Biopharma Solutions (ABS) as a premium service for biopharmaceutical companies interested in adopting multiplex immunofluorescence (mIF) workflows and spatial biomarker development in their translational pathology and immunotherapy programs. ABS is a component of Akoya\u2019s broader Clinical Research Program, a strategic initiative which aims to support the implementation of the Company\u2019s Phenoptics\u2122 mIF platform and spatial phenotypic signatures for precision pathology, through partnerships with academic medical centers, contract research organizations (CROs), reference labs, and the biopharmaceutical … Continue reading "Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T12:28:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications\",\"datePublished\":\"2021-06-02T12:28:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/\"},\"wordCount\":810,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/\",\"name\":\"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=\",\"datePublished\":\"2021-06-02T12:28:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/","og_locale":"en_US","og_type":"article","og_title":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications - Market Newsdesk","og_description":"Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials MARLBOROUGH, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company\u00ae, today announced the launch of Advanced Biopharma Solutions (ABS) as a premium service for biopharmaceutical companies interested in adopting multiplex immunofluorescence (mIF) workflows and spatial biomarker development in their translational pathology and immunotherapy programs. ABS is a component of Akoya\u2019s broader Clinical Research Program, a strategic initiative which aims to support the implementation of the Company\u2019s Phenoptics\u2122 mIF platform and spatial phenotypic signatures for precision pathology, through partnerships with academic medical centers, contract research organizations (CROs), reference labs, and the biopharmaceutical … Continue reading \"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-02T12:28:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications","datePublished":"2021-06-02T12:28:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/"},"wordCount":810,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/","name":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=","datePublished":"2021-06-02T12:28:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzE4NCM0MjIzMTU4IzIyMDc1MDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-announces-rollout-of-strategic-clinical-research-program-to-advance-adoption-of-spatial-biology-for-clinical-applications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499994"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}